Skip to main
ARTV

ARTV Stock Forecast & Price Target

ARTV Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artiva Biotherapeutics Inc is advancing a promising pipeline of allogeneic NK cell therapies, with positive enrollment trends suggesting strong investor interest and confidence in the product’s safety and efficacy. The company’s bull case forecasts a significant increase in the probability of success (POS) for its AlloNK candidate, with the potential for substantial upside as new clinical data is expected to emerge. Notably, Artiva’s current market valuation shows a modest premium based on anticipated cash projections, indicating room for potential appreciation as the company progresses in its clinical trials and continues to receive regulatory support.

Bears say

Artiva Biotherapeutics Inc exhibits a negative outlook primarily due to the inherent risk associated with its lead candidate, AlloNK, which faces the potential for an unfavorable initial clinical data release in 1H:25, indicating its inability to achieve deep B-cell aplasia or tolerance issues. This scenario could dramatically lower the probability of success (POS) for the product to as low as 10%, suggesting a downside of approximately 25% from the base case projections. Additionally, the company's overall performance is undermined by concerns regarding the viability of its NK cell therapy platform to generate further successful clinical candidates, thereby increasing uncertainty surrounding its future growth and financial stability.

ARTV has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artiva Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artiva Biotherapeutics Inc (ARTV) Forecast

Analysts have given ARTV a Buy based on their latest research and market trends.

According to 4 analysts, ARTV has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artiva Biotherapeutics Inc (ARTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.